matrix™
GEL•SYSTEM

MATRIX™ ERYGEN - PO	102700015	1 x 5 ml
	102700010	1 x 10 ml
MATRIX™ ERYGEN - AS	102700032	3 x 2 ml
	102700035	3 x 5 ml
MATRIX™ ERYGEN - ID	102700112	11 x 2 ml

MATRIX™ ERYGEN - PO
MATRIX™ ERYGEN - AS
MATRIX™ ERYGEN - ID

0.8% Reagent Red Blood Cells for Antibody Screening & Identification

SUMMARY

MATRIX™ ERYGEN - PO/AS/ID are reagent red cell suspension for antibody screening and identification. For the sensitive detection of irregular antibodies, specific test systems, such as gel or column agglutination system, based on antigen/antibody reaction are required. The reliability of antibody detection depends widely on homozygous expression of blood group antigens, appropriate enhancement media and anti globulin techniques.

REAGENTS

MATRIX™ ERYGEN - PO/AS/ID are selected cells from known blood group of 'O donors' in optimal antigen presentation for detection of the most frequent clinically significant antibodies. The cells are 0.8% suspension prepared in a special preservation medium. The suitable antigen profile sheet is included with every lot, which broadly can be used to detect and identify the antibody which can cause incompatibility.

STORAGE AND STABILITY

Store at 2-8 ^{0}C. Do not freeze. The usage is limited by the expiry date on the vial label. The antigenicity of the cells may decrease during the shelf life due to the physiological ageing process.

ADDITIONAL REAGENTS AND MATERIALS REQUIRED

Appropriate gel cards and reagents for antibody detection and gel card centrifuge, incubator 37 ^{0}C, pipettes and dispenser.

SAMPLE COLLECTION

No special preparation of the patient is required prior to sample collection by approved techniques. For optimal results, freshly collected samples should be used. Anticoagulants like EDTA, CPD-A and Citrate can be used. Serum or plasma samples can be used. Samples should be centrifuged at 1500g for 10 minutes to avoid fibrin residue which may interfere with results.

NOTE

1. In vitro diagnostic reagent for laboratory and professional use only. Not for medicinal use.
2. **MATRIX™ ERYGEN - PO/AS/ID** should not be pooled or transferred into another container.
3. Do not use hemolysed, lipemic and icteric samples.
4. Each donor unit was nonreactive for HBsAg, anti-HCV, anti-HIV1+2 when tested with licensed reagents. No test method can assure that products of human source will not transmit the causative organism. Products from human blood should be considered potentially infectious.
5. Positive and negative controls should be included as recommended by national guidelines/GLP.
6. Mixed field reactions should be considered positive and needs further evaluation.

APPLICATION OF MATRIX™ ERYGEN - PO/AS/ID

Strictly follow the manufacturer instructions for use for test procedure.
Gently resuspend the cells by inverting the vial several times (10-20 times). Red cells should be well suspended and at room temperature before use. Avoid contamination or changing of the vial pipettes.

INTERPRETATION OF RESULTS

No agglutination indicates: No antibody against any corresponding red cell antigen is detectable.
Agglutination indicates: Antibodies against one or more red cell antigens are detectable.
Hemolysis : Indicate antigen/antibody reaction.
Refer Antigen Chart provided with the kit.

REFERENCES

1. AABB, Technical Manual, 16th Edition, American Association of Blood Banks, 2008.
2. Harvey G. Klein and D. J. Anstee: Mollison's Blood transfusion in Clinical Medicine, 11th Edition, Blackwell Publishing, 2005.
3. P.D. Issitt and D. J. Anstee: Applied Blood Group serology, 4th Edition, Montgomery scientific Publications, 1988.
4. Data on file: Tulip Diagnostics (P) Ltd.

ERG-AS/0716/AE/VER-2

TULIP DIAGNOSTICS (P) LTD.
PLOT NOS. 92/96, PHASE II C, VERNA IND. EST.,
VERNA, GOA - 403 722, INDIA.
Website : www.tulipgroup.com